Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

881 - FRIEND:A Randomized Pilot study to compare the Efficacy and Tolerability of Fulvestrant 500mg with Exemestane as First line endocrine therapy for Post-M ER Positive HER2 negative ABC patients relapse after adjuvant Non-steroidal Aromatase Inhibitors (NSAI)


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


jiayu wang


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


J. wang, B. Xu, Q. Li, P. Zhang, P. Yuan, F. Ma, Y. Luo, R. Cai, Y. Fan, S. Chen, Q. Li

Author affiliations

  • The Department Of Medical Oncology, National Caner Center,Cancer Hospital,Chinese Academy of Medical Science, 100021 - Beijing/CN


Abstract 881


Breast cancer is one of the most common malignancies in women. It has long been acknowledged that oestrogen acts as an endocrine growth factor for hormone-dependent breast cancer. Fulvestrant is a selective estrogen receptor degrader – an ER antagonist with a novel mode of action. Confirm & China Confirm study demonstrated that the efficacy of Fulvestrant 500mg is superior to 250mg. FIRST&FALCON study results confirmed the superior efficacy of fulvestrant over anastrozole in postmenopausal women who have not received prior hormonal therapy. But in the clinical practice, AI are widely used as adjuvant ET for postmenopausal ER+ breast cancer patients. To date there are no randomized trials to compare Fulvestrant 500mg with AI in patients who have relapsed during or after adjuvant non-steroidal AI.

Trial design

The FRIEND trial is a parallel-group, multi-centre study designed to compare the efficacy and tolerability of fulvestrant 500 mg with exemestane 25 mg as first line endocrine therapy in post-M women with ER positive HER2 negative ABC who have relapsed on or after at least 2 years of adjuvant NSAI therapy. Approximately 148 postmenopausal women with ER positive HER2 negative advanced breast cancer who have relapsed whilst on adjuvant NSAI (treatment duration ≥2 years) or after completed adjuvant NSAI treatment will enter this study. Eligible patients will be randomized 1:1 to the following treatment groups: Fulvestrant 500 mg i.m. every 28 (± 3) days plus an additional 500 mg on day 15 (± 3) of first month only; Exemestane 25 mg, orally, once daily. Treatment will continue until disease progression or treatment discontinuation. The primary endpoint is progression-free survival. Secondary endpoints include objective response rate, disease control rate, time to treatment failure, duration of response and overall survival. Efficacy will be determined based on tumor assessments performed by each investigator according to RECIST version 1.1. Safety will be monitored based on the frequency and severity of adverse events (AEs). This study is currently recruiting patients.

Clinical trial identification


Legal entity responsible for the study



AstraZeneca China


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.